What happened with CLRB today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Cellectar Biosciences is a late-stage clinical drug developer. Its proprietary delivery platform links radioactive isotopes to molecules designed to enter cancer cells while limiting exposure to healthy cells. Its lead candidate, iopofosine I 131, has been studied in blood cancers and other tumors, including cancers that have resisted previous treatments.
Research and development remains its main activity, and investors supplying equity capital have been its principal source of operating funds. It is also pursuing development and commercialization partnerships. For iopofosine, the company is assessing funding for a confirmatory study following FDA communications about accelerated approval and a regulatory submission. Drug sales depend on successful development and regulatory approval; even after approval, it may market a drug only for authorized uses and patient groups.
Cellectar relies on outside organizations to run clinical trials and manufacture its candidates. AtomVie is its primary supplier of finished iopofosine. Continuing development depends on securing additional financing, and limited liquidity has raised substantial doubt about the company’s ability to continue operating.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Cellectar's prospects depend on clinical success and funding for its radioconjugates, with AtomVie supplying its primary iopofosine drug product and Ionetix supplying key radioisotopes.
Actinium Pharmaceuticals offers a reference for Cellectar's iodine-131 cancer treatment: its Iomab-B uses the same isotope as iopofosine, but with different delivery systems and clinical targets. Watch Iomab-B's regulatory progress and payments from commercialization partner Immedica, rather than treating it as a direct substitute for iopofosine.
Cerenome overlaps with Cellectar in developing radiation-based drugs for pediatric brain cancers: Cellectar studies iopofosine in relapsed or refractory pediatric high-grade gliomas, while Cerenome develops rhenium obisbemeda for CNS cancers. Watch results for rhenium obisbemeda in pediatric brain cancers, rather than Cerenome's separate tumor-cell testing business.
Perspective Therapeutics and Cellectar both depend on progress in delivering radiation to cancer cells, using peptides and phospholipid carriers respectively. Perspective's alpha therapies remained in clinical development with no product-sales revenue in 2024 or 2025, so their development progress—not its NIH-funded research revenue—is the relevant comparison for Cellectar.
Radiopharm Theranostics shares Cellectar's exposure to whether tumor-targeting molecules can successfully deliver radioactive cancer treatments; Radiopharm uses peptides, small molecules and antibodies, while Cellectar uses phospholipid carriers. Radiopharm has no products approved for sale, making clinical results and approvals for its solid-tumor candidates more relevant than sales comparisons.
Aktis Oncology is a reference for partnering demand around radioactive cancer drugs as Cellectar develops its actinium-225 program, CLR 225. Lilly pays Aktis to research partnered candidates through initial human imaging studies and then takes over clinical development and commercialization; progress in those programs is more informative than product sales, which Aktis had none of in 2024 or 2025.
Bicycle Therapeutics offers a different test of delivering radioactive payloads to tumors: it uses synthetic peptides, while Cellectar uses phospholipid carriers. Watch Bicycle's human imaging studies, which may help select targets and cancer indications for later treatments; its revenue comes mainly from collaborators rather than product sales.
Molecular Partners offers a comparison for the partner funding Cellectar seeks for its cancer-targeting radioconjugates, having pursued targeted radiation-drug development with Novartis. All its revenue in 2023 and 2024 came from that collaboration, with revenue recognition ending in the third quarter of 2024—a concrete reminder to distinguish partner payments from continuing drug sales.
Cellectar Biosciences INC earningsThis company
Cellectar's report will show whether its cash and research spending can keep its cancer-drug studies moving while it seeks the funding to develop them.
Read the cash balance and cash used in operations alongside research spending, and note any new financing the company reports. Cash lasting longer or new funding, with research continuing, would give Cellectar more time to carry out its plans. Cash falling without new funding, while research still needs money, would point to possible delays or cuts.
Aktis Oncology, Inc. earningsAKTS
Aktis's report will show whether Lilly-backed radioactive cancer-drug programs are advancing into human imaging studies, offering a reference for the partnership model Cellectar seeks.
Look for whether the partnered programs advance into human imaging studies and whether Aktis reports continuing partner support. Progress would show a partner funding early research, relevant to Cellectar's effort to develop cancer drugs with outside backing. Stalled programs or weaker support would make that model a less encouraging reference, but would not show that Cellectar cannot find a partner.
Actinium Pharmaceuticals, Inc earningsATNM
Actinium's report will show regulatory progress and partner support for Iomab-B, another iodine-131 cancer treatment and a reference point for Cellectar's iopofosine.
Read Iomab-B's regulatory progress alongside any payments or support from commercialization partner Immedica that Actinium reports. Regulatory advances with continued partner support would show one iodine-131 cancer-drug program moving along its path; setbacks or weaker support would illustrate hurdles it still faces. Iomab-B uses a different delivery system and has different clinical targets from iopofosine, so it is a reference, not a prediction of iopofosine's outcome.
